The effect of recombinant-human-erythropoietin treatment on tumor radiosensitivity and cancer-associated anemia in the mouse

B JOINER, VK HIRST, SR McKeown, JJA MCALEER, DG HIRST

    Research output: Contribution to journalArticle

    21 Citations (Scopus)

    Abstract

    Recombinant human erythropoietin (rHuEpo) has recently become available for the treatment of chronic anaemia, including that associated with cancer. Carcinoma NT in CBA mice causes a progressive anaemia which can be overcome by daily injections of recombinant human erythropoietin (rHuEpo). This model was used to study the effect of haematocrit on tumour blood flow, growth rate and radiosensitivity, in mice with haematocrits ranging from approximately 38% (control) to 65% (20 U/day rHuEpo). Tumours showed a small but significant slowing in growth rate with higher haematocrit. In vitro studies showed rHuEpo had no direct effect on the growth of NT cells. Tumour-blood flow was measured by two methods in each mouse (Xe-133 clearance and Rubidium-86 uptake). Blood flow showed a tendency to decrease with increasing blood viscosity although this effect was not significant despite the large differences in haematocrit. Although tumour doubling time was prolonged despite the large differences in haematocrit. Although tumour doubling time was prolonged with increasing radiation dose, from 0 (sham irradiated) to 35 Gy, haematocrit was not found to influence the growth delay. This was attributed, to adaptation of the tumour during the relatively slow change in the haematocrit. rHuEpo is being considered for clinical use in anaemic cancer patients. Our data suggest that this treatment will correct haematocrit with no effect on tumour radiosensitivity.
    LanguageEnglish
    Pages720-726
    JournalBRITISH JOURNAL OF CANCER
    Volume68
    Issue number4
    Publication statusPublished - Oct 1993

    Fingerprint

    Radiation Tolerance
    Erythropoietin
    Hematocrit
    Anemia
    Neoplasms
    Therapeutics
    Growth
    Rubidium
    Inbred CBA Mouse
    Blood Viscosity
    Radiation
    Carcinoma
    Injections

    Cite this

    JOINER, B ; HIRST, VK ; McKeown, SR ; MCALEER, JJA ; HIRST, DG. / The effect of recombinant-human-erythropoietin treatment on tumor radiosensitivity and cancer-associated anemia in the mouse. In: BRITISH JOURNAL OF CANCER. 1993 ; Vol. 68, No. 4. pp. 720-726.
    @article{d4c14e469a85488486f6d8404190f093,
    title = "The effect of recombinant-human-erythropoietin treatment on tumor radiosensitivity and cancer-associated anemia in the mouse",
    abstract = "Recombinant human erythropoietin (rHuEpo) has recently become available for the treatment of chronic anaemia, including that associated with cancer. Carcinoma NT in CBA mice causes a progressive anaemia which can be overcome by daily injections of recombinant human erythropoietin (rHuEpo). This model was used to study the effect of haematocrit on tumour blood flow, growth rate and radiosensitivity, in mice with haematocrits ranging from approximately 38{\%} (control) to 65{\%} (20 U/day rHuEpo). Tumours showed a small but significant slowing in growth rate with higher haematocrit. In vitro studies showed rHuEpo had no direct effect on the growth of NT cells. Tumour-blood flow was measured by two methods in each mouse (Xe-133 clearance and Rubidium-86 uptake). Blood flow showed a tendency to decrease with increasing blood viscosity although this effect was not significant despite the large differences in haematocrit. Although tumour doubling time was prolonged despite the large differences in haematocrit. Although tumour doubling time was prolonged with increasing radiation dose, from 0 (sham irradiated) to 35 Gy, haematocrit was not found to influence the growth delay. This was attributed, to adaptation of the tumour during the relatively slow change in the haematocrit. rHuEpo is being considered for clinical use in anaemic cancer patients. Our data suggest that this treatment will correct haematocrit with no effect on tumour radiosensitivity.",
    author = "B JOINER and VK HIRST and SR McKeown and JJA MCALEER and DG HIRST",
    year = "1993",
    month = "10",
    language = "English",
    volume = "68",
    pages = "720--726",
    journal = "BRITISH JOURNAL OF CANCER",
    issn = "0007-0920",
    number = "4",

    }

    JOINER, B, HIRST, VK, McKeown, SR, MCALEER, JJA & HIRST, DG 1993, 'The effect of recombinant-human-erythropoietin treatment on tumor radiosensitivity and cancer-associated anemia in the mouse', BRITISH JOURNAL OF CANCER, vol. 68, no. 4, pp. 720-726.

    The effect of recombinant-human-erythropoietin treatment on tumor radiosensitivity and cancer-associated anemia in the mouse. / JOINER, B; HIRST, VK; McKeown, SR; MCALEER, JJA; HIRST, DG.

    In: BRITISH JOURNAL OF CANCER, Vol. 68, No. 4, 10.1993, p. 720-726.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The effect of recombinant-human-erythropoietin treatment on tumor radiosensitivity and cancer-associated anemia in the mouse

    AU - JOINER, B

    AU - HIRST, VK

    AU - McKeown, SR

    AU - MCALEER, JJA

    AU - HIRST, DG

    PY - 1993/10

    Y1 - 1993/10

    N2 - Recombinant human erythropoietin (rHuEpo) has recently become available for the treatment of chronic anaemia, including that associated with cancer. Carcinoma NT in CBA mice causes a progressive anaemia which can be overcome by daily injections of recombinant human erythropoietin (rHuEpo). This model was used to study the effect of haematocrit on tumour blood flow, growth rate and radiosensitivity, in mice with haematocrits ranging from approximately 38% (control) to 65% (20 U/day rHuEpo). Tumours showed a small but significant slowing in growth rate with higher haematocrit. In vitro studies showed rHuEpo had no direct effect on the growth of NT cells. Tumour-blood flow was measured by two methods in each mouse (Xe-133 clearance and Rubidium-86 uptake). Blood flow showed a tendency to decrease with increasing blood viscosity although this effect was not significant despite the large differences in haematocrit. Although tumour doubling time was prolonged despite the large differences in haematocrit. Although tumour doubling time was prolonged with increasing radiation dose, from 0 (sham irradiated) to 35 Gy, haematocrit was not found to influence the growth delay. This was attributed, to adaptation of the tumour during the relatively slow change in the haematocrit. rHuEpo is being considered for clinical use in anaemic cancer patients. Our data suggest that this treatment will correct haematocrit with no effect on tumour radiosensitivity.

    AB - Recombinant human erythropoietin (rHuEpo) has recently become available for the treatment of chronic anaemia, including that associated with cancer. Carcinoma NT in CBA mice causes a progressive anaemia which can be overcome by daily injections of recombinant human erythropoietin (rHuEpo). This model was used to study the effect of haematocrit on tumour blood flow, growth rate and radiosensitivity, in mice with haematocrits ranging from approximately 38% (control) to 65% (20 U/day rHuEpo). Tumours showed a small but significant slowing in growth rate with higher haematocrit. In vitro studies showed rHuEpo had no direct effect on the growth of NT cells. Tumour-blood flow was measured by two methods in each mouse (Xe-133 clearance and Rubidium-86 uptake). Blood flow showed a tendency to decrease with increasing blood viscosity although this effect was not significant despite the large differences in haematocrit. Although tumour doubling time was prolonged despite the large differences in haematocrit. Although tumour doubling time was prolonged with increasing radiation dose, from 0 (sham irradiated) to 35 Gy, haematocrit was not found to influence the growth delay. This was attributed, to adaptation of the tumour during the relatively slow change in the haematocrit. rHuEpo is being considered for clinical use in anaemic cancer patients. Our data suggest that this treatment will correct haematocrit with no effect on tumour radiosensitivity.

    M3 - Article

    VL - 68

    SP - 720

    EP - 726

    JO - BRITISH JOURNAL OF CANCER

    T2 - BRITISH JOURNAL OF CANCER

    JF - BRITISH JOURNAL OF CANCER

    SN - 0007-0920

    IS - 4

    ER -